Evaluation of RFC Transporter & MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.
N/A
15 Years
N/A
15 Years
N/A
Open (Enrolling)
Both
Acute Lymphoblastic Leukemia.
Both
Acute Lymphoblastic Leukemia.
Trial Information
Evaluation of RFC Transporter & MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.
Inclusion Criteria:
- AGe: older than 15 years.
- Male, female.
- Normal renal & liver functions.
- Without previos treatment.
- Candidate to be treated with hyperCVAD Schema.
Exclusion Criteria:
- Patients not candidate to recieve methotrexate or cytarabine.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
To evaluate clinical response
Outcome Description:
To evaluate clinical response after ending Hyper-CVAD schema
Outcome Time Frame:
December 2012
Safety Issue:
No
Principal Investigator
myrna candelaria, md
Investigator Role:
Principal Investigator
Investigator Affiliation:
Instituto Nacional de Cancerología Mexico
Authority:
MEXICO: Federal Comission to protect sanitary risks. Healthy Ministerium
Study ID:
010/020/ICI
NCT ID:
NCT01307241
Start Date:
December 2010
Completion Date:
December 2013
Related Keywords:
- Acute Lymphoblastic Leukemia.
- Acute lymphoblastic leukemia
- prognostic factor
- pharmacogenetics.
- Leukemia
- Leukemia, Lymphoid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Name | Location |
|---|
